Previous close | 11.00 |
Open | 10.93 |
Bid | 10.72 x 1000 |
Ask | 10.73 x 1300 |
Day's range | 10.57 - 10.99 |
52-week range | 6.25 - 13.30 |
Volume | 3,469,535 |
Avg. volume | 9,599,472 |
Market cap | 12.069B |
Beta (5Y monthly) | 1.46 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 27 Nov 2017 |
1y target est | N/A |
Since 2015, Teva stock has lost nearly 80% of its value in the face of loss of exclusivity on key branded drugs. In fact, Buffett still himself owns 42.8 million shares, or a 3.8% stake in the company. Will Teva be able to lead Buffett and contrarian investors alike to riches?
When I look for new investments, I'm usually looking for stocks that I think will rapidly expand for the next few years. Plus, it might be on the hook for new overhead costs pertaining to making its facilities safer in light of the risk of contagion moving forward.
Teva Pharmaceutical Industries Limited ( NYSE:TEVA ) shareholders are probably feeling a little disappointed, since its...